- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00176618
The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon
December 10, 2009 updated by: University of Medicine and Dentistry of New Jersey
The purpose of this study is to determine the effectiveness of curcumin in reducing the number of aberrant crypt foci (ACF) in the colon.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Laboratory studies have indicated that this agent, which is derived from plants and found in foods we eat, has anti-inflammatory properties and prevents colon cancer in animal studies.
ACFs are small abnormalities in the lining of the colon that with time may grow into colorectal adenomas (also called polyps, growths or small masses of tissue on the lining of the colon or rectum which have the potential to become cancerous) which can then grow into adenocarcinomas (cancer) in the colon or rectum.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Cancer Institute of New Jersey
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must be eligible for colorectal cancer (CRC) screening/surveillance by current criteria.
- Subjects must have at least 5 ACF on eligibility chromosigmoidoscopy examination.
Exclusion Criteria:
Subjects must not have:
- Alcohol consumption of greater than 2 glasses of wine or beer per day or illicit recreational drug use
- Platelet or coagulation abnormalities, or personal history of a bleeding disorder, including individuals taking warfarin.
- High risk for developing endocarditis (history of endocarditis or rheumatic fever, cardiac valve prostheses, or mitral valve prolapse that requires antibiotic prophylaxis).
- Uncontrolled hypertension, diabetes, or chronic congestive heart failure.
- Renal insufficiency defined as a serum creatinine > 2.5 mg/dl
- History of colorectal surgery with removal of the distal 60 cm of colon or rectum.
- History of other gastrointestinal mucosal epithelial diseases (such as Barrett's esophagus, chronic or recurrent peptic ulcer disease, celiac sprue or other disorders of nutrient absorption).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effects of curcumin or the NSAID sulindac on the number of ACF in the left colon and rectum of normal volunteers found to have them on an initial magnifying chromoendoscopic screening exam
Time Frame: 48 months
|
48 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the turnover (proliferation, apoptosis, and differentiation) of colorectal epithelial cells in the crypts in situ in response to each treatment
Time Frame: 48 months
|
48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yang CS, MD, Rutgers, the State University of New Jersey
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Primary Completion (Actual)
June 1, 2007
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Estimate)
December 11, 2009
Last Update Submitted That Met QC Criteria
December 10, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Precancerous Conditions
- Aberrant Crypt Foci
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antineoplastic Agents
- Curcumin
- Sulindac
Other Study ID Numbers
- 4611
- CINJ#120305
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aberrant Crypt Foci
-
National Cancer Institute (NCI)CompletedTobacco Use Disorder | Healthy, no Evidence of DiseaseUnited States
-
National Naval Medical CenterNational Cancer Institute (NCI); Uniformed Services University of the Health...CompletedColorectal NeoplasmsUnited States
-
Medical Research CouncilCompletedAberrant DNA Methylation
-
Hugo W. Moser Research Institute at Kennedy Krieger...Completed
-
Drexel UniversityUnknownGlioblastoma Multiforme | Astrocytoma Anaplastic Foci
-
Rutgers, The State University of New JerseyRecruiting
-
Georgia State UniversityRecruitingAggression | Alcohol Drinking | Emotion RegulationUnited States
-
MedSIREli Lilly and CompanyActive, not recruitingBreast Cancer MetastaticItaly, Spain, Portugal
-
Rutgers, The State University of New JerseyAutism SpeaksRecruitingAggression | Problem Behavior | Self-InjuryUnited States
-
Selcuk UniversityCompletedIntellectual Disability | Therapeutic Recreation | Recreational Activities | Aberrant BehaviorsTurkey
Clinical Trials on sulindac
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.Active, not recruiting
-
Alison StopeckMedical University of South Carolina; Cedars-Sinai Medical CenterRecruitingBreast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; Amrita Institute of Sciences,... and other collaboratorsCompletedLeukoplakia, Oral | Benign NeoplasmsUnited States, India
-
Mayo ClinicNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Healx LimitedWithdrawnFragile X SyndromeUnited States, Australia
-
Cancer Prevention Pharmaceuticals, Inc.CompletedFamilial Adenomatous PolyposisUnited States, Belgium, Germany, Canada, Netherlands, Spain, United Kingdom
-
University of UtahNational Cancer Institute (NCI)CompletedAdenomatous Polyposis ColiUnited States
-
National Cancer Institute (NCI)University of ArizonaCompletedBreast CancerUnited States
-
Cancer Prevention Pharmaceuticals, Inc.WithdrawnFamilial Adenomatous Polyposis
-
Duke UniversityJohns Hopkins University; National Cancer Institute (NCI); Memorial Sloan Kettering... and other collaboratorsRecruitingIPMN | IPMN, PancreaticUnited States